中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Viral Diseases
NASH/PBC
Cancer
Exploratory Indications
Products&Pipeline
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Ascletis’ IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA
2019-01-03
Ascletis’ Ganovo Enrolled in the Basic Medical Insurance of Chengdu
2019-01-02
«
1
2
3
浙公网安备 33010802003344号 浙ICP备11050387号-1
